About PER
Back to Homepage
News

About Physicians' Education Resource®, LLC
Accredited by the Accreditation Council for Continuing Medical Education (ACCME), Physicians' Education Resource®, LLC (PER®) is the certified medical education resource of choice for live and online activities focusing on oncology and hematology. Based on identified needs and practice gaps, PER® provides high-quality, evidence- based activities featuring leading national and international faculty with a focus on practice-changing advances and standards of care in treatment and disease management. PER® serves the oncology health care community, including physicians, fellows, physician assistants, advanced practice nurses, nurses, pharmacists and researchers. Learn more at www.gotoper.com.
Title
Publish Date
Physicians' Education Resource® Names Hope Rugo, M.D., FASCO, as the Recipient of the 2020 PER® Educator of the Year Award
Nov 06, 20
COVID-19 Statement
Jul 14, 20
FDA approves lumacaftor/ivacaftor for pediatric cystic fibrosis
Aug 08, 18
First ever IDH1 inhibitor approved for R/R AML
Jul 20, 18
Third BRAF/MEK inhibitor approved for the treatment of advanced melanoma
Jun 27, 18
Pembrolizumab now approved in cervical cancer
Jun 13, 18
Venetoclax granted regular approval for chronic lymphocytic leukemia
Jun 08, 18
Daratumumab approved for newly diagnosed patients in multiple myeloma
May 08, 18
Dabrafenib/trametinib combination approved for second disease state this week
May 04, 18
Tisagenlecleucel approved for second indication: Large B-cell lymphoma
May 01, 18
BRAF/MEK inhibitor combination approved for adjuvant melanoma
May 01, 18
Immune thrombocytopenia gets new approval in fostamatinib
Apr 19, 18
Osimertinib expanded to frontline NSCLC
Apr 19, 18
FDA approves immunotherapy combination for frontline renal cell carcinoma
Apr 16, 18
FDA expands approval of blinatumomab to include MRD-positive ALL
Mar 29, 18
Nilotinib approved for pediatric CML
Mar 22, 18
FDA grants regular approval to brentuximab vedotin in untreated Hodgkin lymphoma
Mar 21, 18
FDA authorizes direct-to-consumer BRCA test
Mar 06, 18
FDA approves new dosing schedule for nivolumab
Mar 06, 18
FDA approves abemaciclib as frontline therapy
Feb 26, 18
FDA approves another checkpoint inhibitor in lung cancer
Feb 16, 18
FDA approves new androgen-receptor inhibitor for nonmetastatic prostate cancer
Feb 15, 18
Peptide receptor radionucleotide therapy approved in the United States
Jan 26, 18
Olaparib approved for BRCA-positive breast cancer
Jan 12, 18
FDA ends year with regular approvals for cabozantinib, pertuzumab, nivolumab
Dec 21, 17
FDA approves oral TKI, bosutinib, for Ph+ CML in the first-line
Dec 20, 17
FDA approves trastuzumab biosimilar for breast and stomach cancers
Dec 01, 17
Breakthrough-designated companion diagnostic approved for over 300 genes, 5 tumor types
Dec 01, 17
Sunitinib Approved for Adjuvant Renal Cell Carcinoma Treatment
Nov 17, 17
Vemurafenib Approved For Rare Blood Cancer
Nov 06, 17
FDA Approves Acalabrutinib for Mantle Cell Lymphoma
Oct 31, 17
FDA Approves Second CAR T-Cell Therapy, Axicabtagene Ciloleucel
Oct 19, 17
FDA Approves Abemaciclib for Advanced or Metastatic Breast Cancer
Sep 28, 17
FDA Approves Copanlisib for Follicular Lymphoma
Sep 14, 17
FDA Approves Bevacizumab Biosimilar for Multiple Cancer Types
Sep 14, 17
FDA Approves Gemtuzumab Ozogamicin for AML
Sep 01, 17
FDA Approves First Ever CAR T-cell Agent, Tisagenlecleucel
Aug 30, 17
In Case You Missed It! Week of August 14 - August 18, 2017
Aug 18, 17
FDA approves olaparib tablets for ovarian cancer maintenance therapy
Aug 17, 17
FDA Approves Inotuzumab Ozogamicin for R/R ALL
Aug 17, 17
In Case You Missed It!
Week of July 31 - August 04
Aug 04, 17
FDA Approves Avelumab for Bladder Cancer
May 09, 17
FDA Approves Brigatinib for ALK-Positive NSCLC
Apr 28, 17
FDA Approves Midostaurin for AML
Apr 28, 17
FDA Approves Regorafenib for Liver Cancer
Apr 27, 17
Transgene and Bristol-Myers Squibb Announce Collaboration to Evaluate TG4010 Vaccine in NSCLC
Apr 27, 17
FDA sends warning over 65 fraudulent cancer treatments
Apr 25, 17
Primary Endpoint Met in MONARCH 3 trial
Apr 24, 17
FDA approves marketing of whole slide imaging management system
Apr 17, 17
FDA Approves Marketing of Whole Slide Imaging System, First of Its Kind
Apr 13, 17
FDA Grants Full Approval to Osimertinib for T790M+ NSCLC
Mar 30, 17
FDA Approves Niraparib for Ovarian Cancer
Mar 27, 17
Report: House GOP Leaders to Delay Vote on Healthcare Bill
Mar 23, 17
FDA Approves Avelumab for Merkel Cell Carcinoma
Mar 23, 17
FDA Approves Pembrolizumab for Hodgkin Lymphoma
Mar 14, 17
FDA Approves Ribociclib for Frontline HR+/HER2- Breast Cancer
Mar 13, 17
FDA Approves Telotristat Ethyl for Carcinoid Syndrome Diarrhea
Feb 28, 17
FDA Approves Maintenance Lenalidomide for Myeloma
Feb 23, 17
FDA Approves Nivolumab for Urothelial Carcinoma
Feb 02, 17
FDA Approves Ibrutinib for Marginal Zone Lymphoma
Jan 19, 17
FDA Approves Rucaparib for Ovarian Cancer
Dec 19, 16
FDA Approves Bevacizumab for Platinum-Sensitive Ovarian Cancer
Dec 07, 16
FDA Approves Daratumumab Triplets for Relapsed Myeloma
Nov 21, 16
FDA Approves Nivolumab for Head and Neck Cancer
Nov 10, 16
FDA Approves Olaratumab for Soft Tissue Sarcoma
Oct 19, 16
FDA Approves Atezolizumab for Lung Cancer
Oct 19, 16
FDA Approves Atezolizumab in Bladder Cancer
May 18, 16
FDA Approves Nivolumab for Hodgkin Lymphoma
May 17, 16
FDA Approves Lenvatinib/Everolimus for Advanced RCC
May 13, 16
FDA Approves Cabozantinib for Renal Cell Carcinoma
Apr 25, 16
FDA Approves Afatinib for Squamous Cell Lung Cancer
Apr 15, 16
FDA Approves Venetoclax for CLL
Apr 11, 16
FDA Approves Defibrotide for Hepatic VOD Following Stem Cell Transplantation
Mar 30, 16
FDA Approves Crizotinib for ROS1-Positive NSCLC
Mar 11, 16
FDA Approves Everolimus for GI, Lung NETs
Feb 26, 16
FDA Approves Obinutuzumab for Follicular Lymphoma
Feb 26, 16
FDA Approves Palbociclib in Pretreated HR+/HER2-Negative Breast Cancer
Feb 19, 16
FDA Approves Eribulin for Advanced Liposarcoma
Jan 28, 16
FDA Expands Nivolumab's Frontline Melanoma Approval to Include BRAF-Mutant Patients
Jan 23, 16
Carfilzomib Combo Approved for Relapsed Multiple Myeloma
Jan 21, 16
FDA Approves Maintenance Ofatumumab in CLL
Jan 19, 16
FDA Approves Two New Indications for Pembrolizumab in Advanced Melanoma
Dec 18, 15
FDA Approves Alectinib for ALK-Positive NSCLC
Dec 11, 15
FDA Approves Elotuzumab for Multiple Myeloma
Nov 30, 15
FDA Approves Necitumumab for Squamous NSCLC
Nov 24, 15
FDA Approves Nivolumab for Metastatic Renal Cell Carcinoma
Nov 23, 15
FDA Approves Ixazomib for Relapsed Multiple Myeloma
Nov 20, 15
FDA Approves Daratumumab for Pretreated Multiple Myeloma
Nov 16, 15
FDA Approves Osimertinib for EGFR T790M-Positive NSCLC
Nov 13, 15
FDA Approves Vemurafenib/Cobimetinib Combo for Melanoma
Nov 10, 15
FDA Approves T-VEC for Advanced Melanoma
Oct 27, 15
FDA Approves Trabectedin in Soft Tissue Sarcoma
Oct 23, 15
FDA Approves MM-398 Regimen for Metastatic Pancreatic Cancer
Oct 22, 15
FDA Expands Nivolumab Lung Cancer Approval
Oct 09, 15
FDA Expands Optune's Glioblastoma Multiforme Indication
Oct 05, 15
FDA Approves Pembrolizumab for PD-L1-Positive Lung Cancer
Oct 02, 15
FDA Approves Nivolumab/Ipilimumab Combination for BRAF Wild-Type Melanoma
Oct 01, 15
FDA Approves TAS-102 for Advanced Colorectal Cancer
Sep 22, 15
FDA Approves Rolapitant for CINV
Sep 02, 15
FDA Expands Carfilzomib's Myeloma Approval
Jul 24, 15
FDA Approves Sonidegib for Basal Cell Carcinoma
Jul 24, 15
FDA Panels Support Approval of T-VEC in Melanoma
Apr 30, 15
FDA Approves Second-Line Ramucirumab for mCRC
Apr 24, 15
FDA Approves Dinutuximab for High-Risk Neuroblastoma
Mar 10, 15
FDA Approves Zarxio as First US Biosimilar
Mar 06, 15
FDA Approves Nivolumab for Lung Cancer
Mar 04, 15
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
     12
3456789
10111213141516
17181920212223
24252627282930
Filter By